Basic Information
| Drug ID | DDPD01211 |
|
| Drug Name | Clarithromycin | |
| Molecular Weight | 747.9534 | |
| Molecular Formula | C38H69NO13 | |
| CAS Number | 81103-11-9 | |
| SMILES | [H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC | |
| External Links | ||
| DRUGBANK | DB01211 | |
| PubChem Compound | 84029 | |
| PDR | 6 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 3.16 | - | 3.16 | - | MCFARLAND,JW ET AL. (1997) |
| Melting Point | 220.0 | ℃ | 220 | ℃ | PhysProp |
| Water Solubility | 0.33 | mg/L | 0.33 | mg/L | DRUGBANK |
| pKa | 8.99 | - | 8.99 | - | MCFARLAND,JW ET AL. (1997) |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| Bioavailability | 55.0 | % | 55±8 | % | PO, oral; | The Pharmacological Basis of Therapeutics | |
| C Max | 2400.0 | ng/ml | 2.4 | mcg/ml | PO, oral; adults; normal,healthy; | The Pharmacological Basis of Therapeutics | C Max | 700.0 | ng/ml | 0.7 | mcg/ml | PO, oral; Derivative; adults; normal,healthy; | The Pharmacological Basis of Therapeutics |
| T Max | 2.8 | h | 2.8 | h | PO, oral; adults; normal,healthy; | The Pharmacological Basis of Therapeutics | T Max | 3.0 | h | 3.0 | h | PO, oral; Derivative; adults; normal,healthy; | The Pharmacological Basis of Therapeutics |
| Clearance | 0.44 | L/h/kg | 7.3±1.9 | ml/min/kg | PO, oral; | Elderly ↓ ;Hepatitis, Hep → ;RD, renal impairment, Renal disease，including uremia ↓ ; | The Pharmacological Basis of Therapeutics | Clearance | 0.44 | L/h/kg | 7.3 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 2.6 | L/kg | 2.6±0.5 | L/kg | Elderly → ;Hepatitis, Hep ↑ ; | The Pharmacological Basis of Therapeutics | Volume of Distribution | 1.5 | L/kg | 1.5 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 3.5 | h | 3-4 | h | DRUGBANK | Half-life | 3.3 | h | 3.3±0.5 | h | PO, oral; | RD, renal impairment, Renal disease，including uremia ↑ ;Hepatic cirrhosis, cirr ↑ ;increasing doses ↑ ;Age ↑ ; | The Pharmacological Basis of Therapeutics | Half-life | 2.8 | h | 2.8 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Eliminate Route | 36.0 | % | 36±7 | % | Urinary excretion; Oral single dose; Unchanged drug; | Elderly → ; | The Pharmacological Basis of Therapeutics |
| Protein Binding | 70.0 | % | ~70 | % | DRUGBANK | Protein Binding | 46.0 | % | 42-50 | % | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for infants | 15.0 | mg/kg/day | 15 | mg/kg/day | PO, oral | Biaxin | clarithromycin | PDR |
| Max dose for infants | 15.0 | mg/kg/day | 15 | mg/kg/day | PO, oral | Biaxin | clarithromycin | PDR |
| Max dose for children | 15.0 | mg/kg/day | 15 | mg/kg/day | PO, oral | Biaxin | clarithromycin | PDR |
| Max dose for children | 30.0 | mg/kg/day | 30 | mg/kg/day | PO, oral | Biaxin | clarithromycin | PDR |
| Max dose for children | 1000.0 | mg/day | 1 | g/day | PO, oral | Biaxin | clarithromycin | PDR |
| Max dose for adolescents | 15.0 | mg/kg/day | 15 | mg/kg/day | PO, oral | Biaxin | clarithromycin | PDR |
| Max dose for adolescents | 30.0 | mg/kg/day | 30 | mg/kg/day | PO, oral | Biaxin | clarithromycin | PDR |
| Max dose for adolescents | 1000.0 | mg/day | 1 | g/day | PO, oral | Biaxin | clarithromycin | PDR |
| Max dose for adults | 1500.0 | mg/day | 1.5 | g/day | PO, oral | Biaxin | clarithromycin | PDR |
| Max dose for adults | 1000.0 | mg/day | 1 | g/day | PO, oral | Biaxin | clarithromycin | PDR |
| Max dose for geriatric | 1500.0 | mg/day | 1.5 | g/day | PO, oral | Biaxin | clarithromycin | PDR |
| Max dose for geriatric | 1000.0 | mg/day | 1 | g/day | PO, oral | Biaxin | clarithromycin | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1